DR. PIERRE DEBS


Associated tags: Research, Curia, Medicine, MD, Medical device, Pharmaceutical industry, Drug discovery, Health, Entrepreneurship, Intelligence, AM, Cannabinoid, Charles University, Drug development, CHMP, PAREXEL, Intel Corporation v. CPM United Kingdom Ltd., GDPR, Cannabis, CIO

Locations: EUROPE, GERMANY

Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform

Retrieved on: 
Tuesday, November 15, 2022
Curia, Intel Corporation v. CPM United Kingdom Ltd., Union, AI, Pharmacology, Doctor of Philosophy, Machine learning, EMA, Artificial intelligence, Algorithm, Patient, Intel, CIO, Cannabis, GDPR, PAREXEL, Medicine, CHMP, Drug development, Research, Charles University, Cannabinoid, AM, Intelligence, Entrepreneurship, Health, Drug discovery, Acquisition, Pharmaceutical industry, Medical device, MD, Ematheudes neurias

FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.

Key Points: 
  • FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.
  • Clinically proven market authorized medications are sine qua non for long-term demands of all stake-holders throughout European healthcare systems, explains Dr. Pierre Debs, Founder and Chief Executive Officer of Chain Pharmaceuticals GmbH.
  • Chain Pharmaceuticals patient data-gathering app, HealChain, is designed with Innoplexus app and its capabilities of data extraction with AI algorithms.
  • Chain Pharmaceuticals GmbH is a German-based drug discovery company using real world data, machine-learning and artificial intelligence to rapidly design and execute clinical trials leading to market-authorized phytocannabinoid products.